The stock rose 5.1% driven by notably strong order intake and upbeat growth in key segments, especially Precision Therapy and new strategic value partnerships, which more than offset ongoing challenges in Diagnostics and a lowered revenue outlook.
- Equipment book-to-bill ratio stood at an impressive 1.27, underpinned by two large value partnerships with leading U.S. health institutions.
- Precision Therapy delivered robust 9% growth, while Imaging growth was softer at 5%, impacted by tough prior year comps and temporary revenue timing shifts.
- Diagnostics segment continued to face structural headwinds, particularly in China, with no improvement yet in the rate of decline.
- The company lowered its fiscal 2026 revenue growth guidance to 3.5%-4.0% (from 4.5%-5.0%), citing continued Diagnostics weakness but raised the EPS guidance due to one-time tariff refunds.
- Innovation momentum remains strong, with advances in photon-counting CTs, DryCool MR technology, radiopharmaceutical capacity expansion, and FDA approval of AI-enabled solutions supporting future growth.
Community Discussion